Scholarlink

Background <p>Laryngeal squamous cell carcinoma (LSCC) is a common and aggressive head and neck malignancy with poor prognosis due to late diagnosis and limited biomarkers. Angiogenesis, driven by vascular endothelial growth factor A (VEGFA), plays a key role in tumor growth and metastasis. Single nucleotide variants (SNVs) in the <i>VEGFA</i> gene have been linked to various cancers, but their role in LSCC remains unclear.</p> Methods <p>In this study, we investigated the association between <i>VEGFA</i> (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) SNV and LSCC susceptibility in a large cohort of 297 LSCC patients and 390 age- and sex-matched control subjects. The DNA samples were obtained from peripheral blood leukocytes, which were purified using the DNA salting-out technique. Real-time polymerase chain reaction assessed SNVs. The data obtained were processed using the IBM SPSS Statistics 29.0 software. Using a detailed subgroup analysis based on tumor stage, size, metastasis, and differentiation grade, we assessed the potential links between <i>VEGFA</i> (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) variants and LSCC development.</p> Results <p>Contrary to previous studies suggesting significant associations between <i>VEGFA</i> genetic variances with other squamous head and neck cell cancers, our study found no statistically significant differences in the distribution of these SNVs between LSCC patients and controls. Our findings suggest that <i>VEGFA</i> SNV may not be a key factor in LSCC susceptibility. However, the complexity of LSCC’s genetic underpinnings warrants further investigation with larger cohorts and additional genetic markers.</p> Conclusions <p>Our results contribute to the ongoing debate on the role of angiogenesis in LSCC and provide insights into the challenges of identifying reliable biomarkers for this malignancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) genotypes in patients with laryngeal squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Agne Pasvenskaite,
  • Alvita Vilkeviciute,
  • Monika Duseikaite,
  • Enrika Pileckaite,
  • Greta Gedvilaite-Vaicechauskiene,
  • Vykintas Liutkevicius,
  • Rasa Liutkeviciene,
  • Virgilijus Uloza

摘要

Background

Laryngeal squamous cell carcinoma (LSCC) is a common and aggressive head and neck malignancy with poor prognosis due to late diagnosis and limited biomarkers. Angiogenesis, driven by vascular endothelial growth factor A (VEGFA), plays a key role in tumor growth and metastasis. Single nucleotide variants (SNVs) in the VEGFA gene have been linked to various cancers, but their role in LSCC remains unclear.

Methods

In this study, we investigated the association between VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) SNV and LSCC susceptibility in a large cohort of 297 LSCC patients and 390 age- and sex-matched control subjects. The DNA samples were obtained from peripheral blood leukocytes, which were purified using the DNA salting-out technique. Real-time polymerase chain reaction assessed SNVs. The data obtained were processed using the IBM SPSS Statistics 29.0 software. Using a detailed subgroup analysis based on tumor stage, size, metastasis, and differentiation grade, we assessed the potential links between VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) variants and LSCC development.

Results

Contrary to previous studies suggesting significant associations between VEGFA genetic variances with other squamous head and neck cell cancers, our study found no statistically significant differences in the distribution of these SNVs between LSCC patients and controls. Our findings suggest that VEGFA SNV may not be a key factor in LSCC susceptibility. However, the complexity of LSCC’s genetic underpinnings warrants further investigation with larger cohorts and additional genetic markers.

Conclusions

Our results contribute to the ongoing debate on the role of angiogenesis in LSCC and provide insights into the challenges of identifying reliable biomarkers for this malignancy.